Drug Trial Radar · NCT00143286
A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation
Last checked: Nov 19, 2026Latest source record: Jun 4, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,000
Actual
Start
Apr 2003
Primary completion
Not stated
Study completion Mar 2005
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 2, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.
Conditions
- Smoking Cessation
Interventions
varenicline (CP-526,555)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Continuous abstinence Weeks 13 -24.
Locations
24 sites in 7 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Santa Ana, California
Pfizer Investigational Site
West Palm Beach, Florida
Pfizer Investigational Site
Lexington, Kentucky
Pfizer Investigational Site
Mogadore, Ohio
Pfizer Investigational Site
Dallas, Texas
Pfizer Investigational Site
Seattle, Washington
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Ottawa, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Cornwall, Prince Edward Island, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Pfizer Investigational Site
Prague, Czechia
Pfizer Investigational Site
Aarhus C, Denmark
Pfizer Investigational Site
Frederikssund, Denmark
Pfizer Investigational Site
Hellerup, Copenhagen, Denmark
Pfizer Investigational Site
Bergen, Norway
Pfizer Investigational Site
Hønefoss, Norway
Pfizer Investigational Site
Oslo, Norway
Pfizer Investigational Site
Gothenburg, Sweden
Pfizer Investigational Site
Helsingborg, Sweden
Pfizer Investigational Site
Stockholm, Sweden
Pfizer Investigational Site
London, United Kingdom
Pfizer Investigational Site
London, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.